Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
Epistemonikos ID: a49a7e9d750235e9d13b3c7e2d935961a5a2955a
First added on: Oct 07, 2026